This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-20. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
=== Other party leaders in parliament === Labour – Chris Hipkins (Leader of the Opposition) Green – Marama Davidson and Chlöe Swarbrick ACT – David Seymour NZ First – Winston Peters Te Pāti Māori – Rawiri Waititi and Debbie Ngarewa-Packer
== Preparation == An aqueous solution of sodium silicate is acidified to produce a gelatinous precipitate that is washed, then dehydrated to produce colorless silica gel. When a visible indication of the moisture content of the silica gel is required, ammonium tetrachlorocobaltate(II) (NH4)2[CoCl4] or cobalt(II) chloride CoCl2 is added. This will cause the gel to be blue when dry and pink when hydrated. Due to a link between the cobalt chloride and cancer, it has been forbidden in Europe for use in silica gel. An alternative indicator is methyl violet, which is orange when dry and green when hydrated.
=== Evaluating similarity === Often the purpose of seeking a structural superposition is not so much the superposition itself, but an evaluation of the similarity of two structures or a confidence in a remote alignment. A subtle but important distinction from maximal structural superposition is the conversion of an alignment to a meaningful similarity score. Most methods output some sort of "score" indicating the quality of the superposition. However, what one actually wants is not merely an estimated "Z-score" or an estimated E-value of seeing the observed superposition by chance but instead one desires that the estimated E-value is tightly correlated to the true E-value. Critically, even if a method's estimated E-value is precisely correct on average, if it lacks a low standard deviation on its estimated value generation process, then the rank ordering of the relative similarities of a query protein to a comparison set will rarely agree with the "true" ordering. Different methods will superimpose different numbers of residues because they use different quality assurances and different definitions of "overlap"; some only include residues meeting multiple local and global superposition criteria and others are more greedy, flexible, and promiscuous. A greater number of atoms superposed can mean more similarity but it may not always produce the best E-value quantifying the unlikeliness of the superposition and thus not as useful for assessing similarity, especially in remote homologs.
(R)-3,4-Methylenedioxy-N-methylamphetamine ([R]-MDMA), also known as (R)-midomafetamine or as levo-MDMA, is the (R)- or levorotatory (l-) enantiomer of 3,4-methylenedioxy-N-methylamphetamine (MDMA; midomafetamine; "ecstasy"), a racemic mixture of (R)-MDMA and (S)-MDMA. Like MDMA, (R)-MDMA is an entactogen or empathogen. It is taken by mouth. The drug is a serotonin–norepinephrine releasing agent (SNRA) and weak serotonin 5-HT2A receptor agonist. It has substantially less or no significant dopamine-releasing activity compared to MDMA and (S)-MDMA. In preclinial studies, (R)-MDMA shows equivalent therapeutic-like effects to MDMA, such as increased prosocial behavior, but shows reduced psychostimulant-like effects, addictive potential, and serotonergic neurotoxicity. In clinical studies, (R)-MDMA produces similar effects to MDMA and (S)-MDMA, but is less potent and has a longer duration. (R)-MDMA was first described in enantiopure form by 1978. Under the developmental code names EMP-01, developed by AtaiBeckley, and DT402 (formerly MM402), developed by Definium Therapeutics (formerly MindMed), it is under development for the treatment of post-traumatic stress disorder (PTSD), social phobia, and pervasive development disorders (PDDs) such as autism. It is thought that (R)-MDMA might have a better safety profile than MDMA itself whilst retaining its therapeutic benefits.
Sources: en.wikipedia.org
== Early life and education == Hagedorn was born in Copenhagen. His father was the captain of a coaster adapted for use as a folk high school ship where aspiring sailors received training in navigation as well as other subjects. Hagedorn attended Hesselager Latin School on Funen. In 1916, he began to study medicine at the University of Copenhagen. During his studies, he worked as an assistant for Carl Julius Salomonsen. He also assisted Christian Bohr.
=== EC 1.1.2 With a cytochrome as acceptor === EC 1.1.2.1: glycerolphosphate dehydrogenase. As the acceptor is now known, the enzyme has been transferred to EC 1.1.5.3, glycerol-3-phosphate dehydrogenase. EC 1.1.2.2: mannitol dehydrogenase (cytochrome) EC 1.1.2.3: L-lactate dehydrogenase (cytochrome) EC 1.1.2.4: D-lactate dehydrogenase (cytochrome) EC 1.1.2.5: D-lactate dehydrogenase (cytochrome c-553) EC 1.1.2.6: polyvinyl alcohol dehydrogenase (cytochrome) EC 1.1.2.7: methanol dehydrogenase (cytochrome c) EC 1.1.2.8: alcohol dehydrogenase (cytochrome c) EC 1.1.2.9: 1-butanol dehydrogenase (cytochrome c) EC 1.1.2.10: lanthanide-dependent methanol dehydrogenase EC 1.1.2.11: glucoside 3-dehydrogenase (cytochrome c)
In Mexico, Applied Biosystems collaborated with the National Institute of Genomic Medicine of Mexico (Instituto Nacional de Medicina Genomica or INMEGEN), and established an Applied Biosystems Sequencing and Genotyping Unit at INMEGEN. In 2006, Applied Biosystems acquired the Research Products Division of Ambion, a supplier of RNA-based reagents and products. That year, with the Influenza A Subtype H5N1 "avian flu" strain scare, the company launched a global initiative to identify and track such infectious diseases. In 2006, Applied Biosystems also acquired Agencourt Personal Genomics, located in Beverly, MA, to commercialize Agencourt's SOLiD sequencing system. In 2007, ABI Solid Sequencing, a next-gen DNA sequencing platform, was announced. Mark Stevenson was appointed president and chief operating officer of Applied Biosystems. In November 2008, Applied Biosystems merged with Invitrogen, forming Life Technologies, which was acquired by Thermo Fisher Scientific in 2014.
== History == In 2013 the company entered an agreement with GlyTech Inc. to cooperate on the production of glycosylated proteins and peptides. In 2015 it bought American Peptide, a bio-technology company in Sunnyvale, California. In the 2020s, Bachem announced and began construction of additional production capacity, including large-scale peptide manufacturing facilities in Bubendorf and the United States.
=== 1999–2003: The Double Duo, The ConstruKction of Light and The Power to Believe === King Crimson reconvened in 1999. With Levin busy with session work, and believing Bruford to be more concerned with his jazz band Earthworks than Crimson, Fripp decided the next phase of King Crimson would be a "Double Duo" of himself, Belew, Gunn, and Mastelotto. This line-up recorded The ConstruKction of Light at Belew's home studio in Mount Juliet, Tennessee. Fripp was inspired by Tool's album Undertow during the writing process of The ConstruKction of Light. Released in May 2000, the album reached No. 129 in the UK. Most of the pieces were metallic, harsh and industrial metal–influenced, featuring Mastelotto performing exclusively on electronic drums, Gunn taking over the bass role on Warr Guitar, and a different take on the interlocking guitars of the 1980s quartet. With the exception of an "industrial blues" sung by Belew through a voice changer (under the pseudonym of "Hooter J. Johnson"), the songs were dense and complex. The album also contained the fourth installment of "Larks' Tongues in Aspic". It received a negative reception for lacking new ideas. At the same time as recording The ConstruKction of Light, the band also recorded an album of improvised instrumentals, Heaven and Earth, released under the name ProjeKct X.
Sources: en.wikipedia.org
The addition of milk to tea in Europe was first mentioned in 1680 by the epistolist Madame de Sévigné. Many teas are traditionally drunk with milk in cultures where dairy products are consumed. These include Indian masala chai and British tea blends. These teas tend to be very hearty varieties of black tea which can be tasted through the milk, such as Assams, or the East Friesian blend. Milk is thought to neutralise remaining tannins and reduce acidity. The Han Chinese do not usually drink milk with tea but the Manchus do, and the elite of the Qing Dynasty of the Chinese Empire continued to do so. Hong Kong-style milk tea is based on British habits. Tibetans and other Himalayan peoples traditionally drink tea with milk or yak butter and salt. In Eastern European countries, and in Russia and Italy, tea is commonly served with lemon juice. In Poland, tea is traditionally served with a slice of lemon and is sweetened with either sugar or honey; tea with milk – called a bawarka ("Bavarian style") in Polish – is common. In Australia, tea with milk is known as "white tea". The order of steps in preparing a cup of tea is a much-debated topic and can vary widely between cultures and individuals. Some say it is preferable to add the milk to the cup before the tea, as the high temperature of freshly brewed tea can denature the proteins found in fresh milk, similar to the change in taste of UHT milk, resulting in an inferior-tasting beverage. Others insist it is better to add the milk to the cup after the tea, as black tea is often brewed as close to boiling as possible.
In chemistry and biology, reactive oxygen species (ROS) are highly reactive chemicals formed from diatomic oxygen (O2), water, and hydrogen peroxide. Some prominent ROS are the hydroperoxide radical or hydroperoxyl (HO2), superoxide (O2−), the hydroxyl radical (OH.), and singlet oxygen (1O2). ROS are pervasive because they are readily produced from O2, which is abundant. Biologically, ROS function as cell signals, are intermediates in the redox behavior of O2, and impact the process of aging.
The biosynthesis of aspartate is a one step reaction that is catalyzed by a single enzyme. The enzyme aspartate aminotransferase catalyzes the transfer of an amino group from aspartate onto α-ketoglutarate to yield glutamate and oxaloacetate. Asparagine is synthesized by an ATP-dependent addition of an amino group onto aspartate; asparagine synthetase catalyzes the addition of nitrogen from glutamine or soluble ammonia to aspartate to yield asparagine. The diaminopimelic acid biosynthetic pathway of lysine belongs to the aspartate family of amino acids. This pathway involves nine enzyme-catalyzed reactions that convert aspartate to lysine.
=== Dihydrolipoyl dehydrogenase (E3) === The dihydrolipoate, covalently bound to a lysine residue of the complex, is then transferred to the Dihydrolipoyl dehydrogenase (E3) active site, where it undergoes a flavin-mediated oxidation, similar in chemistry to e.g. thioredoxin reductase. First, FAD oxidizes dihydrolipoate back to its lipoate (disulfide) resting state, producing FADH2. Then, the substrate NAD+ oxidizes FADH2 back to its FAD resting state, producing NADH and H+.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.